[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR083792A1 - PHARMACEUTICAL COMPOSITION TO TREAT HCV INFECTIONS - Google Patents

PHARMACEUTICAL COMPOSITION TO TREAT HCV INFECTIONS

Info

Publication number
AR083792A1
AR083792A1 ARP110104158A ARP110104158A AR083792A1 AR 083792 A1 AR083792 A1 AR 083792A1 AR P110104158 A ARP110104158 A AR P110104158A AR P110104158 A ARP110104158 A AR P110104158A AR 083792 A1 AR083792 A1 AR 083792A1
Authority
AR
Argentina
Prior art keywords
formula
pyrimidin
furan
fluorine
amino
Prior art date
Application number
ARP110104158A
Other languages
Spanish (es)
Inventor
Michael Thomas Brandl
Karen Elizabeth Olocco
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR083792A1 publication Critical patent/AR083792A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición sólida de tableta o de cápsula de uso oral formada por un primer componente granular que contiene la 4-amino-1-((2R,3R,4R,5R)-3-flúor-4-hidroxi-5-hidroximetil-3-metil-tetrahidro-furan-2-il)-1H-pirimidin-2-ona de fórmula (1a) y por lo menos un ingrediente farmacéuticamente activo antiviral adicional elegido entre el grupo formado por el 4-flúor-1,3-dihidro-isoindol-2-carboxilato de (Z)-(1S,4R,6S,14S,18R)-14-tert-butoxicarbonilamino-4-ciclopropanosulfonilaminocarbonil-2,15-dioxo-3,16-diaza-triciclo[14.3.0.04,6]nonadec-7-en-18-ilo de fórmula (2), el isobutirato de (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pirimidin-1-il)-4-flúor-2-isobutiriloximetil-4-metil-tetra-hidro-furan-3-ilo de fórmula (1b) y el isobutirato de (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pirimidin-1-il)-2-azido-3,4-bis-isobutiril-oxi-tetrahidro-furan-2-ilmetilo de fórmula (3) y un aglutinante.Reivindicación 13: Uso de una composición según una cualquiera de las reivindicaciones de 1 a 12 para el tratamiento de infecciones del HCV.Claim 1: A solid tablet or capsule composition for oral use formed by a first granular component containing 4-amino-1 - ((2R, 3R, 4R, 5R) -3-fluorine-4-hydroxy-5- hydroxymethyl-3-methyl-tetrahydro-furan-2-yl) -1 H -pyrimidin-2-one of formula (1a) and at least one additional pharmaceutically active antiviral ingredient chosen from the group consisting of 4-fluorine-1, (Z) 3-dihydro-isoindole-2-carboxylate (1S, 4R, 6S, 14S, 18R) -14-tert-butoxycarbonylamino-4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-3,16-diaza-tricycle [ 14.3.0.04.6] nonadec-7-en-18-yl of formula (2), the isobutyrate of (2R, 3R, 4R, 5R) -5- (4-amino-2-oxo-2H-pyrimidin-1 -yl) -4-fluorine-2-isobutyryloxymethyl-4-methyl-tetra-hydro-furan-3-yl of formula (1b) and the isobutyrate of (2R, 3S, 4R, 5R) -5- (4-amino -2-oxo-2H-pyrimidin-1-yl) -2-azido-3,4-bis-isobutyryl-oxy-tetrahydro-furan-2-ylmethyl of formula (3) and a binder. Claim 13: Use of a composition according to any one of claims 1 to 1 2 for the treatment of HCV infections.

ARP110104158A 2010-11-09 2011-11-08 PHARMACEUTICAL COMPOSITION TO TREAT HCV INFECTIONS AR083792A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41181010P 2010-11-09 2010-11-09

Publications (1)

Publication Number Publication Date
AR083792A1 true AR083792A1 (en) 2013-03-20

Family

ID=45044542

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104158A AR083792A1 (en) 2010-11-09 2011-11-08 PHARMACEUTICAL COMPOSITION TO TREAT HCV INFECTIONS

Country Status (3)

Country Link
AR (1) AR083792A1 (en)
TW (1) TW201300106A (en)
WO (1) WO2012062691A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6122879B2 (en) * 2012-06-05 2017-04-26 武田薬品工業株式会社 Solid preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633766B1 (en) 2003-05-30 2019-03-06 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acyl sulfonamides as inhibitors of hcv replication
JP4979710B2 (en) 2005-12-09 2012-07-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antiviral nucleoside
ATE482690T1 (en) * 2005-12-14 2010-10-15 Hoffmann La Roche HCV PRODRUG FORMULATION
DK2389164T3 (en) * 2009-01-21 2014-09-15 Hoffmann La Roche PHARMACEUTICAL COMPOSITIONS INCLUDING AN HCV POLYMERASE INHIBITOR PRO DRUG
AR075584A1 (en) * 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.

Also Published As

Publication number Publication date
TW201300106A (en) 2013-01-01
WO2012062691A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
EA201270738A1 (en) MODULATORS OF PHARMACOKINETIC PROPERTIES OF MEDICINES
PE20130198A1 (en) SOLID COMPOSITIONS
WO2010084115A3 (en) Antiviral agents
BR112012018670A2 (en) combination, use of a compound, pharmaceutical composition, and patient pack
EA201490477A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PROPYLENE GLYCOL-HYDRATE DAPAGLYFLOSINE
MX341299B (en) Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor.
UY30819A1 (en) DERIVATIVES OF PIRAZOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
NO20092476L (en) Antibacterial polycyclic urea compounds
EA201001368A1 (en) HETEROCYCLIC UREA DERIVATIVES AND METHODS OF THEIR APPLICATION-211
AR090456A1 (en) PHARMACEUTICAL COMBINATIONS THAT INCLUDE AN ANALOG OF THIONUCLEOTIDES
EA200971081A1 (en) PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7
RU2585622C3 (en) TETRACYCLIC COMPOUNDS
EA201170772A1 (en) ORGANIC COMPOUNDS
CL2008000899A1 (en) Compounds derived from 3-imidazolyl-indolyl, inhibitors of the interaction between p53 and mdm2 and / or mdm4; preparation procedure; pharmaceutical composition; and use in the treatment and / or prophylaxis of proliferative diseases.
EA201100927A1 (en) CYCLIC ANALOGUES 4-AMINO-4-OXOBUTANOIL-PEPTIDES, VIRUS REPLICATION INHIBITORS
NO20081628L (en) Benzodiazepines as HCV inhibitors
EA201070483A1 (en) NEW OPHTHALMOLOGICAL COMPOSITIONS
CY1111442T1 (en) Piperidine compounds and their uses
CO2019002246A2 (en) Bicyclic Nitrogenous Heterocyclic Compound
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
EA201001858A1 (en) HETEROCYCLIC DERIVATIVES OF UREA FOR THE TREATMENT OF BACTERIAL INFECTIONS
EA201001859A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AND METHODS FOR THEIR APPLICATION
PH12018500378B1 (en) Novel annelated phenoxyacetamides
EA200601901A1 (en) COMPOSITIONS CONTAINING IMMUNE MODULATING COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF THE COURSE OF MYELODYLASTIC SYNDROME AND METHODS USING
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal